Zoe Diana Draelos, M.D., is a consulting professor of dermatology, Duke University School of Medicine, Durham, N.C. She is investigator, Dermatology Consulting Services, High Point, N.C., and a Dermatology Times Editorial Advisor and co-medical editor.

Articles

In this month's Cosmetic Conundrums column, Dermatology Times® Chief Medical Editor Zoe Diana Draelos, MD, explores the world of eyebrows, including microblading, grooming, and shape. 

Examining Eyebrows

Hair regrowth was observed after starting dupilumab treatment in some pediatric patients with a history of severe and refractory alopecia areata (AA) and concomitant atopic dermatitis (AD).

Dupilumab for Pediatric Alopecia Areata 

New TrichoTest aims to help clinicians diagnose and treat alopecia.  

First Genetic Test for Hair Loss

Nutrafol launches a new nutraceutical, called Postpartum, aimed at helping women’s hair health post-pregnancy. 

Nutrafol Launches Postpartum Nutraceutical

Trichoscopy, which is based on dermoscopy, can be a valuable tool for diagnosing conditions that cause hair loss and inflammatory scalp disease.

Trichoscopy Advances Hair and Scalp Disease Diagnoses

New study data presented at EADV demonstrated an association between COVID-19 severity in male patients and the sex hormone androgen.

Biomarker Associated with Hair Loss Also Linked to COVID-19 Severity

Futuristic tools including robotics and new types of lasers are just some of the therapeutic innovations aimed at slowing hair loss and increasing hair growth.

Hair Restoration Goes High-Tech

New data on the safety and efficacy of roflumilast foam (ARQ-154, Arcutis Biotherapeutics) for scalp and body psoriasis was presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2021.

Study: Roflumilast Foam Safe, Effective for Scalp and Body Psoriasis

Phase 2 data adds to evidence showing efficacy of JAK inhibitors for treating alopecia areata, for which there are no FDA-approved treatments.

Baricitinib Demonstrates Positive Outcomes for Alopecia Areata

Eli Lilly and Incyte announce results from its phase 3 study evaluating baricitinib 2 mg and 4 mg for the treatment of alopecia areata, making it the first Phase 3 study with top-line results in patients with the hair disorder.

Hair & Scalp